"Ua ʻike mākou mai kā mākou hoʻohana ʻana iā DBS no kahi kokoke i ʻelua mau makahiki e mālama i nā maʻi neʻe e like me ka maʻi Parkinson a me ka haʻalulu koʻikoʻi ʻo ke kaʻina hana he lāʻau palekana a maʻamau hoʻi i ʻae ʻia," wahi a Kauka Whiting. ʻOi aku ma mua o 160,000 poʻe ma ka honua holoʻokoʻa i loaʻa i ka DBS therapy no kēlā mau kūlana.
ʻO AHN kekahi o nā pūnaewele 20 wale nō ma ʻAmelika Hui Pū ʻIa i koho ʻia e komo i ka Advance II Study e mālama ʻia nei ma Kanada a me Kelemānia.
ʻO ka maʻi o Alzheimer ke ʻano maʻamau o ka dementia. Ua manaʻo ʻia he 6.2 miliona, a i ʻole hoʻokahi o ʻeiwa ʻAmelika makahiki 65 a ʻoi aʻe e noho nei me Alzheimer; ʻO 72 pakeneka he 75 makahiki a ʻoi paha. ʻO ka maʻi Alzheimer kahi maʻi holomua a ma kona mau pae hope, ua pili nā neurons i nā ʻāpana o ka lolo e hiki ai i ke kanaka ke hana i nā hana maʻamau o ke kino, e like me ka hele a me ka ʻai ʻana. ʻO ka maʻi ka hopena i ka make a ʻaʻohe mea i ʻike ʻia he lāʻau lapaʻau.
ʻO DBS no ka maʻi Alzheimer e pili ana i ka hoʻohana ʻana i kahi mea i hoʻokomo ʻia e like me ka puʻuwai pacemaker a me ʻelua mau uwea i hoʻopili ʻia e hāʻawi pololei i nā pulu uila māmā i kahi o ka lolo i kapa ʻia ʻo ka fornix (DBS-f), pili i ka hoʻomanaʻo a me ke aʻo ʻana. Manaʻo ʻia ka hoʻoulu ʻana i ka uila e hoʻāla i ke kaapuni hoʻomanaʻo i loko o ka lolo e hoʻokala i kāna hana.
ʻO ka haʻawina randomized, double-blind e mau makahiki ʻehā no nā mea komo, e loaʻa kēlā me kēia o lākou i kahi loiloi Alzheimer maʻamau ma mua o ka hoʻokomo ʻia ʻana o ka neurostimulator. E hoʻohana ʻia nā hopena o kēia loiloi kino, noʻonoʻo, a me ka noʻonoʻo ma ke ʻano he ana kumu no ka loiloi mau ʻia no ka nui o ka piʻi ʻana o Alzheimer i loko o ka lōʻihi o ke aʻo ʻana.
Ma hope o ka hoʻokomo ʻana, ʻelua hapakolu o ka poʻe maʻi e hoʻokaʻawale ʻia e hoʻāla ʻia kā lākou neurostimulator a ʻo ka hapakolu e haʻalele i kā lākou hāmeʻa. ʻO ka poʻe maʻi i pio i ka hoʻomaka ʻana o ke aʻo ʻana e hoʻāla ʻia ma hope o 12 mau mahina.
I loko o ka hoʻokolohua lapaʻau, e nānā ʻia nā poʻe noiʻi e kahi hui multidisciplinary o AHN neurologists, psychiatrists a me neurosurgeons, me Kauka Whiting a me kekahi hoa AHN neurosurgeon a me DBS specialist Nestor Tomycz, MD.
No ke kūpono i ka hoʻokolokolo, pono nā mea maʻi he 65 a ʻoi aku paha, i ʻike ʻia me ka Alzheimer's haʻahaʻa, aia i ke olakino maikaʻi ʻē aʻe, a loaʻa kahi kahu mālama a i ʻole kekahi lālā o ka ʻohana e hele pū me lākou i nā kipa kauka.
"ʻO nā hopena o nā hana mua o kēia hoʻokolohua lapaʻau ke hoʻohiki nei a hōʻike i ka lāʻau lapaʻau hiki ke hoʻopōmaikaʻi i nā poʻe maʻi me ka maʻi Alzheimer ma o ka hoʻopaʻa ʻana a me ka hoʻomaikaʻi ʻana i kā lākou hana cognitive," wahi a Kauka Whiting. "ʻO ka ʻōlelo ʻana he hopena kūleʻa o kēia noiʻi hiki ke hoʻololi i ke ola no nā miliona o ʻAmelika i hoʻopilikia ʻia e kēia maʻi hoʻohaʻahaʻa, ʻaʻole ia he haʻahaʻa. ʻOliʻoli mākou i ka lilo ʻana i waena o nā pūʻulu ʻokoʻa kaulana i ka honua e hāʻawi ana i nā poʻe maʻi o Alzheimer i ke komo ʻana i kēia hana hou.
Ma lalo o ke alakaʻi ʻana a Kauka Whiting, ua lōʻihi loa ka Halemaʻi Nui o Allegheny o AHN ma ke alo o nā hana paionia e holomua i ka hoʻohana ʻana i ka hoʻoulu ʻana i ka lolo hohonu. ʻO ka haukapila ka mua ma ke komohana o Pennsylvania i hoʻohana i ka ʻenehana no ka mālama ʻana i ka haʻalulu koʻikoʻi a me ka maʻi o Parkinson, a ʻo ka mea hou loa, ua hoʻomaka ʻo Kauka Whiting a me kāna hui i ka lua o ka hoʻokolohua lapaʻau e ʻimi ana i ka pono o DBS e kōkua i ka mālama ʻana i ka momona momona.
He aha e lawe ʻia mai kēia ʻatikala:
- DBS for Alzheimer’s involves the use of an implanted device similar to a heart pacemaker and two attached wires that deliver mild electrical pulses directly to an area of the brain called the fornix (DBS-f), which is associated with memory and learning.
- Alzheimer’s is a progressive disease and in its late stages, the neurons in parts of the brain that enable a person to carry out basic bodily functions, such as walking and swallowing are affected.
- The results of this physical, psychological, and cognitive evaluation will be used as a baseline measurement as they are regularly assessed for the rate of Alzheimer’s progression throughout the duration of the study.
